Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). Authors: Charu ...

Adult subjects with locally advanced, unresectable or metastatic, relapsed or refractory LMS were treated with escalating doses of unesbulin orally twice per week in combination with DTIC 1,000 mg/m 2 ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ...

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma ...

The Y-90 resin microspheres demonstrated a 98.5% best overall objective response rate, with all patients responding to the treatment.

Meeting Coverage > GICS New Standard for Unresectable Hepatocellular Carcinoma? — Adding durvalumab and bevacizumab to transarterial chemoembolization almost doubles PFS by Charles Bankhead ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

The per protocol analysis included 74 patients — 36 in the liver transplant group and 38 in the chemotherapy only group. In this analysis, 5-year overall survival was 73% in the transplant group ...

Meeting Coverage > GICS High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer — Three-fourths of patients had clear margins after surgery by Charles Bankhead, Senior ...

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other ...